---
title: "THRD.US (THRD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/THRD.US/news.md"
symbol: "THRD.US"
name: "THRD.US"
parent: "https://longbridge.com/en/quote/THRD.US.md"
datetime: "2026-03-14T00:03:58.116Z"
locales:
  - [en](https://longbridge.com/en/quote/THRD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/THRD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/THRD.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/THRD.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/THRD.US/news.md)


# THRD.US (THRD.US) — Related News

### [Third Harmonic Bio | 10-Q: FY2025 Q1 EPS Beats Estimate at USD 0.35](https://longbridge.com/en/news/239342816.md)
*2025-05-08T12:02:18.000Z*
### [Third Harmonic Bio Announces Plan of Liquidation and Dissolution](https://longbridge.com/en/news/235850475.md)
*2025-04-14T11:06:43.000Z*
> Third Harmonic Bio, Inc. has announced a Plan of Liquidation and Dissolution, approved by its Board of Directors, pendin

### [Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23](https://longbridge.com/en/news/233625548.md)
*2025-03-28T11:39:17.000Z*
> Third Harmonic Bio has an average rating of Hold and mean price target of $4.63, according to analysts polled by FactSet

### [Third Harmonic Bio reports strong 2024 financial results. THB335 Phase 1 data for urticaria indicate progression to Phase 2 trial.](https://longbridge.com/en/news/233458241.md)
*2025-03-27T12:32:46.000Z*
> Newly released data from the Phase 1 trial of THB335 shows promising results, indicating its potential for further devel